other names
{{ Info.Overview }}
Revenue {{ Info.Revenue | formatUSD }}
Headquarters {{ Info.Headquarters }}

Adviser Profile

As of Date 05/31/2024
Adviser Type - Large advisory firm
Number of Employees 28 12.00%
of those in investment advisory functions 17 41.67%
Registration SEC, Approved, 7/2/2015
Other registrations (1)
AUM* 5,911,150,000 6.40%
of that, discretionary 5,911,150,000 6.40%
Private Fund GAV* 5,911,150,000 6.40%
Avg Account Size 1,970,383,333 6.40%
SMA’s No
Private Funds 1
Contact Info 212 xxxxxxx
Websites

Client Types

- Pooled investment vehicles

Advisory Activities

- Portfolio management for pooled investment vehicles

Compensation Arrangments

- A percentage of assets under your management
- Performance-based fees

Recent News

Reported AUM

Discretionary
Non-discretionary
6B 5B 4B 3B 2B 2B 794M
2015 2016 2017 2018 2019 2020 2021 2022 2023

Private Funds



Employees

Private Funds Structure

Fund Type Count GAV
Fund TypeHedge Fund Count1 GAV$5,911,150,000

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM #Funds
Adviser WESTPORT CAPITAL PARTNERS LLC Hedge Fund6.7b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV6.7b AUM6.5b #Funds30
Adviser SPX CAPITAL MANAGEMENT LLC Hedge Fund5.1b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV5.1b AUM359.7m #Funds15
Adviser VR ADVISORY SERVICES LTD. Hedge Fund6.4b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV6.4b AUM6.4b #Funds2
Adviser EMPYREAN CAPITAL PARTNERS, LP Hedge Fund5.0b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV5.0b AUM5.0b #Funds1
Adviser SOUTHEASTERN ASSET MANAGEMENT INC. Hedge Fund131.0m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV131.0m AUM5.3b #Funds3
Adviser LEADENHALL CAPITAL PARTNERS Hedge Fund2.4b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV2.4b AUM4.7b #Funds9
Adviser EXCHANGE TRADED CONCEPTS, LLC Hedge Fund- Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV- AUM5.5b #Funds-
Adviser EMSO ASSET MANAGEMENT LIMITED Hedge Fund553.2m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV553.2m AUM4.5b #Funds3
Adviser CANDLESTICK CAPITAL MANAGEMENT LP Hedge Fund6.1b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV6.1b AUM6.1b #Funds2
Adviser ROCK SPRINGS CAPITAL Hedge Fund5.8b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV5.8b AUM5.8b #Funds2

Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
Stck Ticker78462F103 Stock NameSPDR S&P 500 ETF TR (PUT) $ Position$2,122,458,000 % Position27.00% $ Change13.00% # Change8.00%
Stck Ticker464287655 Stock NameISHARES TR (PUT) $ Position$1,947,744,000 % Position25.00% $ Change5.00% # Change9.00%
Stck Ticker69366J200 Stock NamePTC THERAPEUTICS INC $ Position$212,904,902 % Position3.00% $ Change8.00% # Change3.00%
Stck Ticker64125C109 Stock NameNEUROCRINE BIOSCIENCES INC $ Position$134,708,443 % Position2.00% $ Change-5.00% # Change-4.00%
Stck Ticker868459108 Stock NameSUPERNUS PHARMACEUTICALS INC $ Position$141,026,000 % Position2.00% $ Change16.00% # Change48.00%
Stck Ticker89422G107 Stock NameTRAVERE THERAPEUTICS INC $ Position$61,650,000 % Position1.00% $ Change7.00% # Change0.00%
Stck Ticker558868105 Stock NameMADRIGAL PHARMACEUTICALS INC $ Position$42,024,000 % Position1.00% $ Change-6.00% # Change-11.00%
Stck Ticker92915B106 Stock NameVOYAGER THERAPEUTICS INC $ Position$41,132,000 % Position1.00% $ Change-5.00% # Change11.00%
Stck TickerG5960L103 Stock NameMEDTRONIC PLC $ Position$64,897,261 % Position1.00% $ Change18.00% # Change30.00%
Stck Ticker670100205 Stock NameNOVO-NORDISK A S $ Position$77,650,560 % Position1.00% $ Change51.00% # Change36.00%

Brochure Summary

Overview

Armistice Capital, LLC (“Armistice”), a Delaware limited liability company, is an investment management firm located in New York that commenced operations on May 1, 2012. Steven J. Boyd (the “Managing Member”) is Armistice’s principal and majority owner. Armistice provides discretionary investment advisory services to private investment funds (the “Funds” or the “Advisory Clients”), which include: Armistice Capital Fund LP, a Delaware limited partnership that launched on July 1, 2012 (the “Domestic Fund”); Armistice Capital Offshore Fund Ltd., an exempted company incorporated under the laws of the Cayman Islands that launched on August 1, 2012 (the “Offshore Fund”); and Armistice Capital Master Fund Ltd., an exempted company incorporated under the laws of the Cayman Islands (the “Master Fund”) that launched on July 1, 2012. The Domestic Fund and the Offshore Fund (together, the “Feeder Funds”) invest substantially all of their assets in the Master Fund, through a master-feeder fund structure. It should also be noted that Armistice Capital GP, LLC (the “General Partner”), an affiliate of Armistice, is also majority owned by Mr. Boyd and acts as General Partner to the Domestic Fund. The Feeder Funds, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing primarily in equity securities, equity-related instruments, debt investments, and other assets. In all
of its investing activities, the Funds seek to emphasize capital preservation and seek to mitigate risk through various hedging strategies at both the position and portfolio levels. To achieve this objective, the Funds seek to focus on strategic value, event, and thematic investment opportunities (both long and short) in a variety of industries. It should be noted that the Funds invest a portion of their assets in illiquid investments (with some limitation), including, investments in securities of non-public companies. While it is anticipated that the Funds will continue to invest primarily in equities and equity-related securities in the both the U.S. and non-U.S. markets, Armistice has broad and flexible investment authority with respect to the Funds. The Funds have entered into and may in the future enter into agreements (“Side Letters”) with certain prospective or existing investors whereby such investors are subject to terms and conditions that are more advantageous than those set forth in the respective Fund’s offering documents. The modifications are solely at the discretion of Armistice and may, among other things, be based on the size of the investor’s investment in the Funds, an agreement by an investor to maintain such investment in the Funds for a significant period of time, or other similar commitment by an investor to the Funds. As of December 31, 2023, Armistice managed approximately $5,911,150,000of regulatory assets on a discretionary basis.